Hypoxia-activated anticancer drugs

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 6, 2005, Pages 635-646

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer chemotherapy; Drug design; Drug diffusion; Hypoxia; Hypoxia activated prodrug

Indexed keywords

ALIPHATIC COMPOUND; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; HETEROCYCLIC COMPOUND; MELPHALAN; MISONIDAZOLE; MITOMYCIN C; NITROIMIDAZOLE; OXIDOREDUCTASE; PIMONIDAZOLE; PORFIROMYCIN; PRODRUG; QUINONE DERIVATIVE; TIRAPAZAMINE; TRANSITION ELEMENT;

ANTINEOPLASTIC ACTIVITY; BACTERIAL GENETICS; CLINICAL TRIAL; CLOSTRIDIA; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; EXTRAVASCULAR SPACE; GENE VECTOR; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE THERAPY; PATENT; RETINA INJURY; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 21244461192     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.6.635     Document Type: Review

References (73)

1. HARRIS AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer (2002) 2:38-47.
2. BROWN JM, WILSON WR: Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer (2004) 4:437-447.
3. EVANS SM, JUDY KD, DUNPHY I et al.: Comparative measurements of hypoxia in human brain rumors using needle electrodes and EF5 binding. Cancer Res. (2004) 64:1886-1892.
4. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br. J. Cancer (2004) 90:2232-2242.
5. 2 tension measurements. Cancer Res. (1991) 51:3316-3322.
6. MOVSAS B, CHAPMAN JD, HORWITZ EM et al.: Hypoxic regions exist in human prostate carcinoma. Urology (1999) 53:11-18.
7. TANNOCK IF, LEE CM, TUNGGAL JK, COWAN DS, EGORIN MG: Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. (2002) 8:878-884.
8. BROWN JM, GIACCIA AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. (1998) 58:1405-1416.
9. DENNY WA, WILSON WR, HAY MP: Recent developments in the design of bioreductive drugs. Br. J. Cancer (1996) 74 (Suppl.27):32-38.
10. DENNY WA: Prodrug strategies in cancer therapy. Eur. J. Med. Chem. (2001) 36:577-595.
11. PRUIJN FB, STURMAN JR, LIYANAGE HDS, HICKS KO, HAY MP, WILSON WR: Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellalar layer cultures. J. Med. Chem. (2005) 48:1079-1087.
12. DENNY WA, WILSON WR: Considerations for the design of nitrophenyl mustards as drugs selectively toxic for hypoxic mammalian cells. J. Med. Chem. (1986) 29:879-887.
13. PALMER BD, WILSON WR, PULLEN SM, DENNY WA: Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. Chem. (1990) 33:112-121.
14. MAUGER AB, BURKE PJ, SOMANI HH, FRIEDLOS F, KNOX RJ: Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. (1994) 37:3452-3458.
15. TERCEL M, LEE AE, HOGG A et al.: Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreduccive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. (2001) 44:3511-3522.
16. PATTERSON LH: Rationale for the use of aliphatic N-oxides of cyrotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Met. Rev. (1993) 12:119-134.
17. WARE DC, PALMER BD, WILSON WR, DENNY WA: Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards are a newclass of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. J. Med. Chem. (1993) 36:1839-1846.
18. TOMASZ M, Y. PALOM Y: The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol. Ther. (1997) 76:73-87.
19. SEOW HA, PENKETH PG, BELCOURT MF, TOMASZ M, ROCKWELL S, SARTORELLI AC: Nuclear overexpression of NAD(P)H:quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of micomycin C under aerobic and hypoxic conditions. J. Biol. Chem. (2004) 279:31606-31612.
20. SARTORELLI AC: Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. (1988) 48:775-778.
21. HAFFTY BG, WILSON LD, SON YH et al.: Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial. Int. J. Radiat. Oncol. Biol. Phys. (2005) 61:119-128.
22. CUMMINGS J, SPANSWICK VJ, GARDINER J, RITCHIE A, SMYTH JF: Pharmacological and biochemical determinants of the antitumor activity of the indoloquinone EO9. Biochem. Pharmacol. (1998) 55:253-260.
23. WINSKI SL, SWANN E, HARGREAVES RH et al.: Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem. Pharmacol. (2001) 61:1509-1516.
24. JAFFAR M, PHILLIPS RM, WILLIAMS KJ et al.: 3-Substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro. Biochem. Pharmacol. (2003) 66:1199-1206.
25. PHILLIPS RM, JAFFAR M, MAITLAND DJ et al.: Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem. Pharmacol. (2004) 68:2107-2116.
26. BREIDER MA, PILCHER GD, GRAZIANO MJ, GOUGH AW: Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol. Pathol. (1988) 26:234-239.
27. DENNY WA, ROBERTS PB, ANDERSON RF, BROWN JM, WILSON WR: NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys. (1992) 22:553-556.
28. PAPADOPOULOU MV, EPPERLY MW, SHIELDS DS, BLOOMER WD: Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds. Jan. J. Cancer Res. (1992) 83:410-414.
29. PAPADOPOULOU MV, BLOOMER WD: NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreducrive drug. Clin. Cancer Res. (2003) 9:5714-5720.
30. PALMER BD, WILSON WR, ANDERSON RF, BOYD M, DENNY WA: Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J. Med. Chem. (1996) 39:2518-2528.
31. WILSON WR, PULLEN SM, HOGG A, HELSBY NA, HICKS KO, DENNY WA: Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. (2002) 62:1425-1432.
32. HELSBY NA, FERRY DM, PATTERSON AV, PULLEN SM, WILSON WR: 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreducrase GDEPT. Br. J. Cancer (2004) 90:1084-1092.
33. BOGER DL, JOHNSON DS: CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew Chem. Int. Ed. (1996) 35:1438-1474.
34. GIESEG MA, MATEJOVIC J, DENNY WA: Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double stranded DNA. Anticancer Drug Des. (1999) 14:77-84.
35. HAY MP, ATWELL GJ, WILSON WR, PULLEN SM, DENNY WA: Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e] indoline minor groove alkylating agents as prodrugs for gene therapy in conjunction with E. coli nitroreductase. J. Med. Chem. (2003) 46:2456-2466.
36. ATWELL G.J, WILSON WR, DENNY WA: Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI. Bioorg. Med. Chem. Lett. (1997) 7:1493-1496.
37. YANG S, DENNY WA: A new short synthesis of 3-substituted-1-(chloromethyl)-2, 3-dihydro-(1H)-benzo[e]indol-5-ylamines (amino-CBIs). J. Org. Chem. (2002) 67:8958-8961.
38. HAY MP, SYKES BM, O'CONNOR CJ, DENNY WA: Substituent effects on the kinetics of reductively-initiated fragmentation of nitrobenzyl carbamates designed as triggers for bioreductive drugs. J. Chem. Soc. Perkin Trans. I (1999) 2759-2770.
39. SHYAM K, PENKETH PG, SHAPIRO M, et al.: Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J. Med. Chem. (1999) 42:941-946.
40. MULCAHY RT, GIPP JJ, SCHMIDT JP, JOSWIG C, BORCH RT. Nitrobenzyl phosphoramidates as potential hypoxia-selective alkylating agents. J. Med. Chem. (1994) 37:1610-1615.
41. HAY MP, SYKES BM, DENNY WA et al.: A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3 H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg. Med. Chem. Lett. (1999) 15:2237-2242.
42. TERCEL M, WILSON WR, ANDERSON RF, DENNY WA: Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreducrive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. (1996) 39:1084-1094.
43. WILSON WR, FERRY DM, TERCEL M, ANDERSON RF, DENNY WA: Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation. Radiat. Res. (1998) 149:237-245.
44. WILSON WR, DENNY WA, PULLEN SM, et al.: Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer (1996) 74 (Suppl.27):43-47.
45. PATTERSON, LH: Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Met. Rev. (2002) 34:581-592.
46. PATTERSON LH, MCKEOWN SR, RUPARELIA K, et al.: Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent. Br. J. Cancer (2000) 82:1984-1990.
47. GALLAGHER R, HUGHES CM, MURRAY MM et al.: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br. J. Cancer (2001) 85:625-629.
48. McCARTHY HO, YAKKUNDI A, McERLANE et al.: Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. (2003) 10:40-48.
49. WELSH S, WILLIAMS R, KIRKPATRICK L, PAINE-MURRIETA G, POWIS G: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol. Cancer Ther (2004) 3:233-244.
50. RISCHIN D, PETERS L, FISHER R et al.: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. (2005) 23:79-87.
51. VON PAWEL J, VON ROEMELING R, GATZEMEIER U et al.: Tirapazamine plus cisplatin versus cisptatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol. (2000) 18:1351-1359.
52. PATTERSON AV, SAUNDERS MP, CHINJE EC, PATTERSON LH, STRATFORD IJ: Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des. (1998) 13:541-573.
53. ANDERSON RF, SHINDE SS, FLAY MP, GAMAGE SA, DENNY WA: Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. (2003) 125:748-756.
54. SHINDE S, ANDERSON RF, HAY MP, GAMAGE SA, DENNY WA: Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-aminobenzotriazine 1,4-dioxides. J. Am. Chem. Soc. (2004) 126:7865-7874.
55. HWANG JT, GREENBERG MM, FUCHS T, GATES KS: Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-scranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry (1999) 38:14248-14255.
56. KOCH CJ: Unusual concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. (1993) 53:3992-3997.
57. HICKS KO, PRUIJN FB, STURMAN JR, DENNY WA, WILSON WR: Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study using multicellular layer cultures. Cancer Res. (2003) 63:5970-5977.
58. HAY MP, DENNY WA: New and versatile syntheses of 3-alkyl-1,2,4-benzotriazine-1,4-dioxides: preparation of the bioreductive cytotoxins SR4895 and SR4941. Tet. Lett. (2002) 43:9569-9571.
59. HAY MP, GAMAGE SA, KOVACS MS et al.: Structure-activicy relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. (2003), 46:169-182.
60. DELAHOUSSAYE YM, HAY MP, PRUIJN FB, DENNY WA, BROWN JM: Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol. (2003) 65:1807-1815.
61. HAY MP, PRUIJN FB, GAMAGE SA et al.: DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. J. Med. Chem. (2004) 47:475-488.
62. SIIM BG, PRUIJN FB, STURMAN JR et al.: Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res. (2004) 64:736-742.
63. SIMIC M, LILIE J: Kinetics of ammonia detachment from reduced cobalt(III) complexes based on conductometric pulse radiolysis. J. Am. Chem. Soc. (1974) 96:291-292.
64. ANDERSON RF, DENNY WA, WARE DC, WILSON WR: Pulse radiolysis studies on the mechanism of hypoxia-selective cytotoxicity of the cobalt(III)-nitrogen mustard complex SN 24771. Br. J. Cancer (1996) 74 (Suppl.27):48-51.
65. PARKER LL, LACY SM, FARRUGIA LJ et al.: A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J. Med. Chem. (2004) 47:5683-5689.
66. AHN G-O, WARE DC, DENNY WA, WILSON WR: Optimization of the auxiliary ligand shell of cobalt(III) (8-hydroxyquinoline) complexes as model hypoxia-setective radiation-activated prodrugs. Radiat. Res. (2004) 162:315-325.
67. WILSON WR, TERCEL M, ANDERSON RF, DENNY WA: Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anticancer Drug Des. (1998) 13:663-685.
68. SHIBAMOTO Y, SUGIE C, ITO M, OGINO H: The Japanese experiences with hypoxia-targeting pharmacoradiotherapy; from hypoxic cell sensitizers to radiation-activated prodrugs. Expert Opin. Pharmacother. (2004) 5:2459-2467.
69. SHIBAMOTO Y, ZHOU L, HATTA H, MORI M, NISHMOTO S: In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49:407-413.
70. HEPPNER F, MOSE JR: The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir. (1978) 42:123-125.
71. FOX ME. LEMMON MJ, MAUCHLINE ML et al.: Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther. (1996) 3:173-178.
72. LEMMON MJ, VAN ZIJL P, FOX ME et al.: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. (1997) 4:791-796.
73. LIU SC, MINTON NP, GIACCIA AJ, BROWN JM: Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. (2002) 9:291-296.